Kornimate/medical-research-clean huggingface dataset:
vaginal packing after laparoscopic sacrocolpopexy

Conditions: Vaginal Packing Following Laparoscopic Sacrocolpopexy; Pelvic Organ Prolapse

Summary: vaginal packing is used routinely following vaginal reconstructive surgery, however, no recommendation regarding vaginal packing after laparoscopic sacrocolpopexy exists. despite little data to support the practice, purported benefits better positioning and fixation of the mesh, improving incorporation of the mesh by its fixation and reduced blood loss. patients often complain of discomfort associated with the packing or its removal. the aim of this randomized controlled is to compare the subjective impressions of pain and bother in women undergoing laparoscopic sacrocolpopexy treated with and without packing. the investigators also aim to assess differences in postoperative bacteriuria, urine retention and hemoglobin levels on day 5 after the surgery and surgery outcome and complications at one year after the surgery in those with and without packing.


Eligibility criteria:
inclusion criteria: * laparoscopic sacrocolpopexy without a suburethral sling * pelvic organ prolapse stage \> 2 * speak and read czech * can to understand the informed consent exclusion criteria: * any other surgery than sacrocolpopexy * concurrent hysterectomy or opening of the vagina during the surgery. * vaginal, uterine, cervical or ovarian malignancy * clotting disorder, taking anticoagulation * having intraoperative blood loss greater than 500 ml

Keywords: vaginal packing pelvic organ prolapse pain and satisfaction
effect of oral helicobacter pylori infection on the efficacy of gastroluminal helicobacter pylori eradication therapy

Conditions: Helicobacter Pylori

Summary: the aim of this study is to assess the effect of oral helicobacter pylori infection on the efficacy of gastric helicobacter pylori infection eradication. patients diagnosed with gastric helicobacter pylori infection are tested for oral helicobacter pylori and given standard bismuth quadruple therapy, with a urea breath test, a rapid urease test, or a helicobacter pylori stool antigen test to confirm gastric helicobacter pylori eradication at week 6 follow-up, and an oral helicobacter pylori test kit to confirm oral helicobacter pylori eradication.


Eligibility criteria:
inclusion criteria: 1. age between 18\~70 ,both gender. 2. initial diagnosis of stomach helicobacter pylori infection or never had helicobacter pylori infection. 3. have not received dental care or systemic periodontal basic treatment in the past 1 year. exclusion criteria: 1. those who have contraindications to the drugs used in this institute or are allergic to the drugs used. 2. there is serious organ damage and complications (such as cirrhosis, uremia, etc.), severe or unstable cardiopulmonary or endocrine diseases. 3. ongoing use of antiulcer medications (including ppis taken within 2 weeks before helicobacter pylori infection testing), antibiotics, or bismuth complexes (more than 3 times/week before screening). 4. those with severe oral diseases and malignant tumors of the mouth. 5. women planning pregnancy, pregnancy and breastfeeding. 6. previously had upper gastrointestinal surgery. 7. those who do not take their medication on time. 8. refusal to sign informed consent.

Keywords: oral helicobacter pylori helicobacter pylori gastric eradication rate of helicobacter pylori in the stomach
a prospective, comparative study to explore the efficacy and safety of the five channels multiway deep transcranial magnetic stimulation (tms) device in subjects with major depression disorder (mdd)

Conditions: Depression

Summary: the multiway stimulator is a novel tms stimulator with several new and unique properties. currently standard tms devices include a single channel, and can operate only a single coil. the multiway stimulator includes five channels which can operate up to five independent tms coils, either simultaneously or sequentially. the multiway device may be used to obtain a differential activation of various brain regions. for instance it can be used to induce high frequency stimulation of a certain brain region, thus inducing facilitation, while simultaneously stimulate at low frequency in another brain region, leading to inhibition. the purpose of the study is to explore the efficacy and safety of multiway deep tms in comparison to a single channel dtms treatment in subjects with mdd. subjects will be treated with one of two designs of the study device (the multiway coil tms device): 1. single channel with a coil placed over the left pfc (10 hz). 2. four channels: a. 10 hz over the left pfc. b. 1 hz over the right pfc. c. 10 hz over the left parietal cortex. d. 1 hz over the right parietal cortex.


Eligibility criteria:
inclusion criteria: * outpatient * diagnosed by senior psychiatrist as suffering from major depression episode according to dsm iv using the structured clinical interview for dsm-4 (scid). * rating on hdrs-21\>20. * age: 18-68 years. * treated for the current depressive episode, at least four weeks, with at least one antidepressant in accepted dose, without improvement, according to their medical chart and athf ( antidepressant treatment history form) instruction guidelines . * gave informed consent for participation in the study. * negative answers on safety screening questionnaire for transcranial magnetic stimulation. exclusion criteria: * diagnosis as suffering from other diagnosis on axis 1 ( like: schizophrenia, bipolar disorder, psychotic depression, geriatric depression). * diagnosis as suffering from severe borderline personality disorder or hospitalized due to exacerbation related to of borderline personality disorder. * substantial suicidal risk as judged by the treating psychiatrist. * attempted suicide in the past year. * any current unstable medical or surgical illness. * history of seizure or heat convulsion. * history of epilepsy or seizure in first degree relatives. * history of head injury. * history of any metal in the head (outside the mouth). * known history of any metallic particles in the eye, implanted cardiac pacemaker or any intracardiac lines, implanted neurostimulators, surgical clips, cochlear implants or any medical pumps. * history of hearing loss. * history of drug abuse or alcoholism in the last 6 month. * pregnancy or not using a reliable method of birth control. * systematic and metabolic unstable disorders. * inadequate communication with the patient. * under custodial care. * participation in current clinical study or clinical study within 30 days prior to this study.
transcranial direct/ alternating current stimulation for parkinson's disease treatment

Conditions: tACS; tDCS

Summary: to investigate the difference in the treatment efficacy between transcranial direct current stimulation and transcranial alternating current stimulation on parkinson's disease, including the improvements in the motor, cognitive, and underlying neural mechanisms behind differences in efficacy by electroencephalography (eeg).

all patients underwent a medical evaluation that include physical examinations and routine laboratory studies before and after stimulation sessions. patients were randomly allocated to tacs, tdcs, and sham groups. there are about 20 patients in each group. allocation was by computer generating random numbers. the decision to enroll a patient was always made prior to randomization. patients were studied using a double-blind design. study participants, clinical raters, and all personnel responsible for the clinical care of the patient remained masked to allocated conditions and allocation parameters. only stimulation administrators had access to the randomization list; they had minimal contact with the patients, and no role in assessing the updrs(unified parkinson´s disease rating scale), hoehn \& yahr, and moca(montreal cognitive assessment). each patient would be treated for 20 minutes of transcranial electrical stimulation. before the stimulation session, updrs, hoehn \& yahr, and moca were obtained by a trained investigator to assess the baseline severity of symptoms. the patients received electroencephalography (eeg) recorded during resting state for 5 minutes. during the stimulation session, patients were asked to perform simple reaction tasks at the same time. after the stimulation session, updrs, hoehn \& yahr, and moca were obtained, as well as the global index of safety（tes side effects） to assess adverse events of the treatment. the patients also received a measure of electroencephalography (eeg) recorded during the resting state.

Eligibility criteria:
inclusion criteria: * diagnosis of idiopathic pd according to the movement disorder society criteria * right-handed * no clinically known hearing or vision impairment * no history of epilepsy, dementia, other brain disorders apart from pd, severe internal organs disease, age-related frailty, etc. exclusion criteria: * parkinsonism due to drugs, cerebrovascular disease, encephalitis, poisoning, traumatic brain injury, etc. * metal implants in the head (i.e., deep brain stimulator or aneurysm clips) * severe somatic or psychiatric disorders that require medication or routinely monitoring * participated in other interventional studies within the past 3 months
the effect of tendon release techniques in patients with cervical disc herniation

Conditions: Cervical Disc Herniation

Summary: the goal of this clinical trial is to investigate the effect of using enhanced golgi tendon organ stimulation on symptoms in patients with cervical disc herniation. the main question\[s\] it aims to answer are: * enhanced golgi tendon organ stimulation is effective in reducing symptoms in patients with cervical disc herniation. * enhanced golgi tendon organ stimulation is not effective in reducing symptoms in patients with cervical disc herniation. participants will receive enhanced golgi tendon organ stimulation to the sternocleidomastoideus, platysma, longus colli, longus capitis, scalene, rhomboid major \& minor, levator scapulae and trapezius muscles for 3 weeks, 2 sessions per week for 45 minutes.

participants diagnosed with cervical disc herniation will be included. participants will receive 6 sessions of 45 minutes each, 2 sessions per week for 3 weeks. sternocleidomastoideus, platysma, longus colli, longus capitis, scalene muscles, rhomboid major \& minor, levator scapulae and trapezius muscles and tendons of these muscles will be applied. two separate applications are performed with the stimulator and the algometer. after increasing the blood flow in the area for 30 seconds with the vibration of the stimulator up to the point of attachment of the tendon, a pressure of 0.5 kilograms is applied at an angle of 90 degrees at 0.5 cm intervals from the origin to the insertion of the muscle in the area with an algometer made of special steel. the aim of this treatment is to stabilise the contraction and relaxation mechanism by stimulating the golgi tendon organ and to eliminate pain by relieving spasms.

Eligibility criteria:
inclusion criteria: * being diagnosed with cervical disc herniation * volunteering for the research exclusion criteria: * chronic bone disease * have had surgery for a cervical disc herniation * have a structural abnormality

Keywords: disc herniation enhanced golgi tendon organ stimulation pain cervical
wearable dark-adaptometer in normal adult healthy volunteers

Conditions: Photoreceptor Sensitivity Thresholds

Summary: conventional dark-adaptometers are unsuitable as a mass screening tool due to their high cost, lack of easy portability, need of trained staff and a totally dark room to be operated, arbitrary testing procedures, associated time waste in clinic and patient burden to mention a few. consequently, dark adaptometers are not routinely used as clinical tools for retinal diagnosis and monitoring despite the inherent benefits over other visual electrophysiology equipment such as the erg system, whose cost and features may often be surplus to optometrists' requirements. this trial will assess the dark-adaptometry testing performance of a novel light-emitting system by generating full dark-adaptation threshold functions in normal adult healthy volunteers. the novel system has been proposed to overcome the issues associated with current instrumentation; it is semi-automatic and easy to use without the need of any skilled operator. it is envisaged that this system could spread the practice of dark-adaptometry testing and its adoption by high-street optometrists. this will allow diagnosing a number of retinal pathologies more quickly and more reliably that, faced with an ageing population, represents a major asset to the health community and the nhs. this trial will involve 20 healthy volunteers, distributed in equal number in 2 groups of 18-40 and 50-70 years old, respectively. proven the good health and eye condition of the participants, one of their eyes will be randomly-allocated and undergo dark-adaptometry testing 3 times on separate days within 3 weeks. testing will clarify whether by using the novel system it is possible to reproduce state-of-the-art threshold measurements as good or better than those produced by commercially-available dark-adaptometers. threshold measurements in the elderly will be compared with literature data adjusted to exclude aged crystalline lens and pupillary miosis contributions. data variability and system usability will be also assessed.

all details elsewhere in the documentation

Eligibility criteria:
inclusion criteria: * refractive error: ≤ ±5 dioptres spherical (myopia/hyperopia) equivalent; ≤ 3 dioptres cylinder (astigmatism) equivalent. exclusion criteria: * subjects not in age range and/or unable to fully understand the informed consent and/or unable to comply with study procedures. * self-reported history of depression, lack of sleep, psychiatric disorders, or neurological diseases such as alzheimer's and parkinson's disease. * self-reported history of diabetes, stroke, or multiple sclerosis. * self-reported hypovitaminosis a, alcoholism, liver or intestinal disease, malabsorption, protein calorie malnutrition, or sickle cell anaemia. * use of psychoactive drugs (including lithium salts for mood stabilisation). * use of dietary intake of ascorbic acid, vitamin a, b, e or other antioxidant supplements in the last two weeks. * recurrent practice of activities that expose the retina to ultra-violet radiation such as sailing, fishing, sunbathing or tanning saloons.
blood-based colorectal cancer (crc) screening implementation into clinical practice highlands

Conditions: Cancer Colon

Summary: this is a prospective implementation study that will include patients that are identified as being average risk for colorectal cancer (crc) according to uspstf guidelines and who have opted to be screened for crc. the purpose of this study is to understand implementation of a noninvasive screening test in primary care and internal medicine clinical settings, and the impact on patient acceptability and adherence of crc screening.

study rationale this is a prospective implementation study that will include patients that are identified as being average risk for colorectal cancer (crc) according to uspstf guidelines and who have opted to be screened for crc. the purpose of this study is to understand implementation of a noninvasive screening test in primary care and internal medicine clinical settings, and the impact on patient acceptability and adherence of crc screening. although multiple screening options for crc are available, participation and adherence to crc screening remains below the national goal. crc screening rate at the ballad health mountain laurel internal medicine clinic (site 1) is approximately 66%. a blood-based test (bbt) can provide a clinically important complement to standard-of-care (soc) screening tests and address unmet medical needs for patients, especially for those who are non-adherent with current screening modalities. there are economic and societal benefits in early detection and prevention of crc in a broader population than the one currently up to date with screening. the unmet need for maximum participation in crc screening could be addressed with blood-based testing. measuring subsequent provider experience and implementation behavior patterns involving blood based non-invasive cancer screening choices will also help to identify clinical utility of such test and implementation into clinical practice.

Eligibility criteria:
inclusion criteria: patients aged 45-84 years of age (inclusive) considered by health-care providers to be "average risk" for crc as determined by uspstf guidelines if a patient opts for blood-based test, they are able and willing to provide blood samples per protocol ability to understand and the willingness to participate in the study exclusion criteria: patients with a personal history of crc patients with a known high-risk family history of crc precluding the patient from being average risk patients with known diagnosis of inflammatory bowel disease or history of polyps patients who are currently symptomatic for crc such as: blood in the stool patients with any known medical condition which, in the opinion of the investigator, should preclude enrollment into the study have a recorded up to date crc screening patients with a previous abnormal colonoscopy finding who are due for surveillance.
extracorporeal membrane oxygenation in coronavirus disease (covid-19), influenza and ards of other ethiologies

Conditions: ARDS; COVID-19; Influenza

Summary: a comparison of clinical characteristics and outcomes of patients on extracorporeal membrane oxygenation (ecmo) in covid-19, influenza and ards of other ethiologies

all ards patients on extracorporeal membrane oxygenation (ecmo) during january 1st 2016 and january 10th 2022 in university medical center ljubljana were included and their clinical characteristics and outcomes were studied according to ards ethiology: covid-19, influenza and other ethiologies.

Eligibility criteria:
inclusion criteria: * patient with acute respiratory distress syndrome (ards) on extracorporeal membrane oxygenation (ecmo) * 18 years or older exclusion criteria: * patient not eligible for ecmo treatment per institutional guidelines (terminal illness, palliative care)

Keywords: extracorporeal membrane oxygenation ards covid-19 influenza
a trial of shr-a1904 in patients with advanced pancreatic cancer

Conditions: Advanced Pancreatic Cancer

Summary: the study is being conducted to assess the safety and tolerability of shr-a1904 in patients with with advanced pancreatic cancer and to determine the dose-limiting toxicity (dlt), maximum tolerated dose (mtd), and recommended phase ii dose (rp2d) of shr-a1904


Eligibility criteria:
inclusion criteria: 1. evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study 2. males or females aged 18-75 years old 3. eastern cooperative oncology group (ecog) performance status of 0-1 4. has a life expectancy of ≥ 3 months 5. has at least one measurable lesion as defined by recist v1.1 exclusion criteria: 1. plan to receive any other anti-tumor treatments during the study treatment period of this study 2. received other clinical investigational products or treatments within 4 weeks before the first dose of the study 3. underwent a major surgery other than diagnosis or biopsy within 4 weeks before the first dose of the study 4. previously received gastrectomy (only for subjects of the dose-escalation part) 5. subjects with known brain metastases 6. grade ii-iv cardiac insufficiency as per the new york heart association (nyha) criteria; arrhythmia requiring long-term drug control; unstable angina or acute myocardial infarction within 6 months before the first dose of the study 7. presence of accompanying diseases (such as poorly controlled hypertension, serious diabetes mellitus, thyroid disorder, psychosis, etc.) that may pose serious risks to the safety of the subject or may affect the subject's ability to complete the study, or any other situation as judged by the investigator
comparison of the pharmacokinetics of tiotropium delivered from test inhaler products with two reference products

Conditions: Healthy

Summary: the purpose of this study is to compare the absorption of three different inhalation products with the reference products in healthy volunteers.

healthy subjects will be enrolled and will receive single doses of 3 test inhalation products and two reference inhalation products according to a five-period cross-over design. plasma tiotropium levels will be measured pre-dose and over 8 hours post-dose.

Eligibility criteria:
inclusion criteria: * healthy volunteer * willing and able to give informed consent * willing to withhold all alcoholic beverages for 48 hours and all xanthine- containing foods and beverages for 24 hours prior to reporting to clinic * subjects must agree to use an adequate method of contraception from admission through 12 weeks after last administration exclusion criteria: * evidence or history of clinically significant abnormalities or disease or chronic respiratory disorders * any presence or history of a clinically significant allergy including any adverse reaction to study drug * history of drug or alcohol abuse within the past 2 years * smoked tobacco within the past 6 months or have a history of more than 10- pack years (number of packs smoked per day x number of years smoked) * donation or loss of greater than 400 ml of blood within the previous 3 months * have received any prescription medication within 4 weeks or investigational medication within 12 weeks of study (exception: contraceptives are permitted) * have received any non-prescription medication within 14 days prior to dosing (exception: paracetamol use within 2 days) * upper respiratory tract infection (excluding otitis media) within 14 days of the first study day, or lower respiratory tract infection within the last 3 months * if female, nursing, lactating or pregnant * regular alcohol consumption in males \>21 units per week and females \>14 units per week (1 unit = ½ pint beer, 25 ml of 40% spirit or a 125 ml glass of wine)

Keywords: inhalation anticholinergic
characterization of pain processing mechanisms in irritable bowel syndrome

Conditions: Irritable Bowel Syndrome

Summary: the purpose of this study is to provide new information and to determine which kinds of brief, tolerable, experimental pain are affected by the drugs being studied in patients with irritable bowel syndrome, a disease that causes chronic abdominal pain. the effects of dextromethorphan, naloxone, and fentanyl on experimental pain stimuli will be tested in these studies to better understand what causes irritable bowel syndrome.


Eligibility criteria:
* patients with irritable bowel syndrome and healthy pain-free individuals (as controls) will be studied. * no medical condition that would contraindicate use of dextromethorphan, fentanyl or naloxone.

Keywords: irritable bowel syndrome visceral hypersensitivity visceral pain